Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Covington
Fuji
Queensland Health
UBS
Daiichi Sankyo
Julphar
Cantor Fitzgerald
Boehringer Ingelheim
US Army

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208030

« Back to Dashboard

NDA 208030 describes FERRIPROX, which is a drug marketed by Apopharma Inc and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FERRIPROX profile page.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferiprone profile page.
Summary for 208030
Tradename:FERRIPROX
Applicant:Apopharma Inc
Ingredient:deferiprone
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 208030
Mechanism of ActionIron Chelating Activity
Suppliers and Packaging for NDA: 208030
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FERRIPROX deferiprone SOLUTION;ORAL 208030 NDA ApoPharma USA, Inc. 52609-4502 N 52609-4502-7

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength100MG/ML
Approval Date:Sep 9, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 14, 2018
Regulatory Exclusivity Use:TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
Patent:➤ Try a Free TrialPatent Expiration:Jun 28, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING CHRONIC IRON OVERLOAD
Patent:➤ Try a Free TrialPatent Expiration:Oct 29, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING CHRONIC IRON OVERLOAD

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Express Scripts
Harvard Business School
Johnson and Johnson
AstraZeneca
Federal Trade Commission
Medtronic
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot